Business
Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...
About this update from Alligator Bioscience Ab
[{"type":"text","content":"NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.","length":355,"tagName":"p"},{"type":"text","content":"LUND, SE / ACCESS Newswire / December 1, 2025 / Alligator Bioscience (STO:ATORX) - On 22 October 2025, the Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") resolved on an issue of units, consisting of ordinary shares and warrants, with preferential rights for the Company's existing shareholders (the "Rights Issue"), where the final terms were resolved and announced on 24 November 2025. At the time of such announcement, the Rights Issue was covered by subscription and guarantee commitments of approximately SEK 78 million, corresponding to up to approximately 64 percent of the Rights Issue. The Company has now received additional subscription undertakings from a number of existing shareholders, including Roxette Photo SA and Magnus Petersson[1], amounting in total to approximately SEK 5.4 million (the "New Subscription Undertakings"). In addition, the Company has received additional guarantee commitments, both from existing shareholders as well as new investors, including HDF Impact BV, amounting in total to SEK 12.5 million (the "New Guarantee Commitments"), which means that the subscription and guarantee commitments thereby have increased from approximately SEK 78 million to approximately SEK 91 million, corresponding to up to approximately 74 percent of the Rights Issue. The New Guarantee Commitments are so-called top guarantee commitments.","length":1456,"tagName":"p"},{"type":"text","content":"Søren Bregenholt, CEO of Alligator Bioscience, comments:"We are encouraged by the continued support from long-term investors, and we are pleased to welcome new shareholders. Their commitment is an important endorsement of our strategy and strengthens our ability to execute on the next steps in Alligator Bioscience's development. Ultimately, this support helps us advance mitazalimab toward the market and closer to the patients who are...